Mark Hyman, MD · 2026-08-12 · Mark Hyman (host), Tyna Moore
What We Got Wrong About GLP-1s (And What's Actually Right)
44 research-tied claims examined: 3 contradicted 4 overstated 6 context 24 supported 7 unverified
3 Contradicted by research
Only approximately 5 to 10% of individuals who lose weight successfully maintain the weight loss long term.
"and I think what, like 5 to 10% of people who go through a weight loss journey will actually keep it off." (said at 0:32:15)
The statement repeats a commonly cited popular figure (that 90–95% of dieters fail and only 5–10% maintain weight loss), which stems from older, uncontrolled 1950s clinical data rather than current epidemiological and clinical evidence. Systematic reviews and cohort studies indicate that approximately 20% of individuals who lose weight successfully maintain a clinically significant weight reduction (defined as maintaining a ≥10% weight loss) for at least one year. Furthermore, prospective population-based cohort data (such as the CARDIA study) show that approximately 34% of individuals who lose ≥5% of their body weight maintain at least 75% of that loss over a 5-year follow-up.
A July 2024 JAMA Ophthalmology study showed an increase in non-arteritic anterior ischemic optic neuropathy (NAION) risk associated with semaglutide of approximately 0.03 percentage points.
"But a study just came out, July 2024, JAMA Ophthalmology, basically showing that it's an increase of about 3/100 of 1 percentage point. It's very, very low." (said at 0:40:54)
The July 2024 JAMA Ophthalmology study by Hathaway et al. evaluated patients at a specialized neuro-ophthalmology registry and reported substantially higher risk estimates than an increase of '0.03 percentage points' (3/100 of 1 percentage point). Over 36 months, the cumulative incidence of nonarteritic anterior ischemic optic neuropathy (NAION) was 8.9% in the semaglutide group versus 1.8% in the non-GLP-1 RA cohort for patients with type 2 diabetes (hazard ratio 4.28), an absolute difference of 7.1 percentage points. In overweight or obese patients, the cumulative incidence was 6.7% with semaglutide versus 0.8% with non-GLP-1 RA medications (hazard ratio 7.64), an absolute difference of 5.9 percentage points. The study did not find an increase of approximately 0.03 percentage points.
- contradicts: Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide… (JAMA ophthalmology 2024) · cited 283x in the literature
"The cumulative incidence of NAION for the semaglutide and non-GLP-1 RA cohorts over 36 months was 8.9% (95% CI, 4.5%-13.1%) and 1.8% (95% CI, 0%-3.5%), respectively. A Cox proportional hazards regression model showed higher risk of NAION for patients receiving semaglutide (hazard ratio [HR], 4.28; 95% CI, 1.62-11.29); P < .001). In the population of patients who were overweight or obese, 20 NAION events occurred in the prescribed semaglutide cohort vs 3 in the non-GLP-1 RA cohort. The cumulative incidence of NAION for the semaglutide vs non-GLP-1 RA cohorts over 36 months was 6.7% (95% CI, 3.6%-9.7%) and 0.8% (95% CI, 0%-1.8%), respectively. A Cox proportional hazards regression model showed a higher risk of NAION for patients prescribed semaglutide (HR, 7.64; 95% CI, 2.21-26.36; P < .001)." (abstract, results, passage verified)
pubmedfull study (doi)
A small study found that GLP-1 receptor agonists can exacerbate androgen excess symptoms.
"and there was one study, it was small. I can't remember if it was on rodents or humans, but it showed that GLP-1s can maybe exacerbate that androgen excess picture a bit." (said at 0:50:20)
The speaker claims that a small study found GLP-1 receptor agonists can exacerbate androgen excess symptoms. However, available evidence in human clinical trials and animal models demonstrates that GLP-1 receptor agonists reduce androgen levels and improve hyperandrogenemia rather than worsening it. In a randomized controlled trial of overweight patients with polycystic ovary syndrome (PCOS), treatment with the GLP-1 receptor agonist liraglutide combined with metformin significantly improved hyperandrogenemia, reducing total testosterone and free androgen index more effectively than metformin monotherapy (PMID 36060969). Similarly, animal studies evaluating long-acting GLP-1 receptor agonists in PCOS models show significant reductions in serum androgen levels and downregulation of ovarian steroidogenic enzymes responsible for androgen synthesis (PMID 34375684).
- contradicts: Dulaglutide, a long-acting GLP-1 receptor agonist, can improve hyperandrogenemia and ovari… (Peptides 2021) · cited 45x in the literature
"Compared with the rats in PCOS group, the serum androgen level of rats in the treatment groups was significantly decreased, and the serum sex hormone binding protein content was significantly increased, and there was statistically significant difference between these groups and PCOS group." (abstract, results, passage verified)
pubmedfull study (doi) - contradicts: Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in… (Frontiers in endocrinology 2022) · cited 78x in the literature
"MET plus LIRA therapy improved hyperandrogenemia, including TT (total testosterone), SHBG (sex hormone binding globulin) and FAI (free androgen index), whereas MET monotherapy only improved SHBG and FAI when compared with baseline." (abstract, results, passage verified)
pubmedfull study (doi)
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.